Greatmark Investment Partners Inc. purchased a new stake in shares of Bausch Health Companies Inc (NYSE:BHC) in the third quarter, HoldingsChannel.com reports. The institutional investor purchased 14,675 shares of the company’s stock, valued at approximately $377,000.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. NEXT Financial Group Inc purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $101,000. Steward Partners Investment Advisory LLC purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $106,000. Polaris Greystone Financial Group LLC purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $107,000. Quadrant Capital Group LLC purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $118,000. Finally, Riggs Asset Managment Co. Inc. purchased a new position in Bausch Health Companies during the 3rd quarter valued at about $174,000. 43.28% of the stock is owned by institutional investors.
A number of brokerages recently issued reports on BHC. Piper Jaffray Companies raised shares of Bausch Health Companies from an “underweight” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $19.00 in a research report on Thursday, September 13th. Royal Bank of Canada set a $30.00 price target on shares of Bausch Health Companies and gave the company a “hold” rating in a research report on Monday, October 8th. JPMorgan Chase & Co. lifted their price target on shares of Bausch Health Companies to $18.00 and gave the company an “underweight” rating in a research report on Wednesday, August 8th. ValuEngine raised shares of Bausch Health Companies from a “sell” rating to a “hold” rating in a research report on Monday, September 24th. Finally, HC Wainwright set a $25.00 price target on shares of Bausch Health Companies and gave the company a “hold” rating in a research report on Monday, October 8th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $26.89.
Bausch Health Companies (NYSE:BHC) last released its quarterly earnings data on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.81 by $0.12. The business had revenue of $2.13 billion during the quarter, compared to analyst estimates of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. Equities research analysts expect that Bausch Health Companies Inc will post 3.46 earnings per share for the current year.
In other news, Director Schutter Richard U. De acquired 125,000 shares of Bausch Health Companies stock in a transaction on Thursday, September 13th. The stock was acquired at an average cost of $23.96 per share, for a total transaction of $2,995,000.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Christina Ackermann sold 19,946 shares of the firm’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $24.98, for a total transaction of $498,251.08. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 165,000 shares of company stock valued at $3,890,700. 11.54% of the stock is owned by company insiders.
About Bausch Health Companies
Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.